2-氨基-3-氰基-5-氟吡啶 、 三乙胺 、 盐酸羟胺 在
EtOAc hexanes 、 SiO2 作用下,
以
乙醇 为溶剂,
反应 6.0h,
以to afford 35 mg of the title compound as a white film (74%)的产率得到2-Amino-5-fluoro-N-hydroxynicotinimidamide
参考文献:
名称:
3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS
申请人:Merck & Co., Inc.
公开号:EP1625123A2
公开(公告)日:2006-02-15
EP1625123A4
申请人:——
公开号:EP1625123A4
公开(公告)日:2007-08-29
[EN] 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS<br/>[FR] 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES SERVANT D'AGONISTES DU RECEPTEUR S1P
申请人:MERCK & CO INC
公开号:WO2004103279A2
公开(公告)日:2004-12-02
The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
申请人:Colandrea J. Vincent
公开号:US20060252741A1
公开(公告)日:2006-11-09
The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.